Clinical Trials
7 trialsNCT06761976 2026-06-04
Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation
Bayer
Available
NCT05572970 2026-05-06
Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
Agenus Inc.
Available
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT02632994 2025-09-29
Master Rollover Protocol for Continued Safety Assessment of Study Drug
Eli Lilly and Company
Available
NCT06980506 2025-05-22
MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
Monopar Therapeutics
Available
NCT06980519 2025-05-22
MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
Monopar Therapeutics
Available
NCT04853602 2024-08-12
IFx-Hu2.0 Expanded Access Program
TuHURA Biosciences, Inc.
Available